Dogwood Therapeutics Stock
Dogwood Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Gregory Duncan
- Employees
- 8
- Market cap
- $41 M
- IPO
- 17/12/2020
- Web
- www.dwtx.com
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of…
Dogwood Therapeutics stock: price history
1D
-2.4%
1W
-12.9%
1M
-28.2%
6M
-26.5%
YTD
-70.7%
1Y
-79.7%
2Y
-72.5%
5Y
-99.0%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~37% weaker price swings than usual
Ask the agents about Dogwood Therapeutics
Analyst assessment of Dogwood Therapeutics
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 19/05/2026
Dogwood Therapeutics stock metrics
P/E
-0.14
P/B
0.61
EV/EBITDA
-1.09
RETURN ON EQUITY
-16.9%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
25.9%
FLOAT SHARES
8,808,027
AVG. DAILY VOLUME (30D)
69,389
Institutional holders
Comparable stocks
Frequently asked questions about Dogwood Therapeutics stock
What does Dogwood Therapeutics do?
Dogwood Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Gregory Duncan, the company employs around 8 people.
The IPO was on 17/12/2020; the stock trades on NASDAQ under the ticker DWTX.
What do analysts say about Dogwood Therapeutics stock?
1 analysts rate the stock, the consensus is Buy (as of 19/05/2026).
This is an external assessment, not a statement by Market Jury.
When does Dogwood Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -37% stronger than usual.
Does Dogwood Therapeutics pay a dividend?
No, Dogwood Therapeutics currently does not pay a dividend.
Which stocks are comparable to Dogwood Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Dogwood Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Dogwood Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.